Apertura Gene Therapy
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
345 Park Ave S Fl 6, New York, New York,...Website
www.aperturagtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Apertura Gene Therapy
Headquartered in New York, NY, Apertura Gene Therapy is a biotechnology company with a focus on genetic medicines for intractable diseases.Explore more
Apertura Gene Therapy Org Chart
JD
Chief Medical Officer, Acting
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Apertura Gene Therapy your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Apertura Gene Therapy recently announced quarterly report
Funding: Get notified immidiatlly once Apertura Gene Therapy has new funding data
Click to see if Apertura Gene Therapy had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Apertura Gene Therapy
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Apertura Gene Therapy has recently received funding, and reach out quickly before it becomes old news!
Check out if Apertura Gene Therapy is spiking on competitors!
Product Launch: Get notified when Apertura Gene Therapy launches new products
Apertura Gene Therapy, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Apertura Gene Therapy
Compare insights from companies similar to Apertura Gene Therapy, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Apertura Gene Therapy is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Apertura Gene Therapy is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Apertura Gene Therapy.
Apertura Gene Therapy financials insights
Gather financial insights about Apertura Gene Therapy, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$67M
Apertura Gene Therapy Tech Stack
A closer look at the technologies used by Apertura Gene Therapy
Apertura Gene Therapy News & Media
Apertura Gene Therapy Named to Consortium Receiving Funding from the Advanced Research Projects Agency for Health (ARPA-H) THRIVE Program to Develop Gene Therapies for Rare Childhood Diseases
—Consortium led by the Broad Institute's Center for Therapeutic Genetics to use Apertura's novel CNS-targeted AAV capsid, TfR1 CapX™, for base and prime gene editing programs— NEW YORK, July 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation...Apertura Gene Therapy Announces Cooperative Research and Development Agreement with Institutes of the NIH to Test Investigational Gene Therapy for Niemann-Pick Disease Type C1
—Cooperative Research and Development Agreement (CRADA) will utilize Apertura's TfR1 CapX™ Capsid— —Ara Parseghian Medical Research Fund, a non-profit organization dedicated to finding a treatment or cure for Niemann-Pick Type C, will contribute financial support to the research— NEW...Apertura Gene Therapy and the TSC Alliance Announce Collaboration to Advance Gene Therapy Programs Designed to Treat Tuberous Sclerosis Complex (TSC)
— Gene therapy programs developed through the collaboration will use Apertura's TfR1 CapX™, a novel, intravenously delivered AAV capsid — NEW YORK AND SILVER SPRING, Md., May 5, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for...Apertura Gene Therapy and Scientists from the Broad Institute to Share Data on TfR1 CapX™, a Novel Capsid Targeting the Central Nervous System (CNS), at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
— Presentations show that TfR1 CapX™ is being manufactured at clinical scale, a major hurdle in gene therapy development, and illustrate the importance of human-relevant preclinical models for gene therapy development — — Presentations on Open Aperture, Apertura's material transfer...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Apertura Gene Therapy
Sign Up For FreeTo access detailed company insights
Headquartered in New York, NY, Apertura Gene Therapy is a biotechnology company with a focus on genetic medicines for intractable diseases.... Read More
